

# How can an inside view with superior visualization offer you a **unique clinical advantage** against major adverse cardiac events (MACE)?

**\$363 billion in costs related to heart attack treatment, rehab, and lost productivity each year<sup>1</sup>**

## Patients (per year)

- Globally, cardiovascular disease kills over 17 million people<sup>1</sup>
- 800,000 Americans suffer from heart attacks<sup>1</sup>
- 200,000 of those Americans experience a second episode<sup>1</sup>

## Healthcare Professionals

- Increased workload because of testing, surveillance, and treatments
- Increased pressure to perform
- Increased stress and the potential for errors

## Hospitals

- Increased costs in medical products for interventional treatment
- Increased costs related to time, personnel, and risks associated with increased demands for care

<sup>1</sup>. <https://www.cdc.gov/heartdisease/facts.htm>

Fryar CD, Chen T-C, Li X. Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999–2010 pdf icon[PDF-494K]. NCHS data brief, no. 103. Hyattsville, MD: National Center for Health Statistics; 2012. Accessed May 9, 2019.

**Major adverse cardiac events have a direct impact on patients, healthcare professionals, and hospitals alike.**

# INTRAVASCULAR IMAGING

Gain clarity from within

## YOUR LINK BETWEEN PATIENT AND CARE

Nipro Medical Corporation is a subsidiary of Nipro Corporation Japan, established in 1954 and a world-leader in healthcare with over 30,000 employees around the globe. We are committed to delivering innovative, high quality solutions in the form of renal, medical-surgical, and vascular products. This fundamental objective drives us to develop cutting-edge, value-added products for healthcare professionals that are safe, effective, and easy to use.

As an integral part of a vast global manufacturing network, Nipro Medical Corporation's North America division is responsible for managing the sales, marketing, and business operations of the United States and Canada – unified in our commitment to improving patient care and quality of life.



VASCULAR



# INTRAVASCULAR IMAGING

Gain clarity from within



[www.nipro.com](http://www.nipro.com)



**NIPRO MEDICAL CORPORATION**  
200 Crossing Blvd., Bridgewater, NJ 08807  
T: +1 (908) 393-7030  
[www.nipro.com](http://www.nipro.com) | [info@nipromed.com](mailto:info@nipromed.com)

© 2022 Nipro Medical Corp. All Rights Reserved.  
NMC-LBL-0163\_21 March 2022-USA-EN




# TWO POWERFUL WAYS TO GAIN CLARITY FROM WITHIN


HF-OCT brought to you by  GENTUITY

## Gentuity® HF-OCT Imaging System

- Designed for total vessel imaging, indicated for the **widest** range of coronary arteries (1.3-6.0 mm) and ideal for radial access with 165 cm working length
- Vis-Rx® Micro-Imaging catheter, the world's **smallest** imaging catheter at 1.8 F with the **fastest** pullback speed for One Second Imaging™ (100 mm in 1 sec)
- Intuitive software and PIM located outside the sterile field, eliminating the need for bagging



Vis-Rx® Micro-Imaging Catheter works exclusively with the Gentuity® HF-OCT system



HF-OCT visualization with access to narrow vasculature and expanded field of view

**Next-generation OCT that's faster, easier, and more powerful than ever**




IVUS+NIRS brought to you by  infraredx™  
A NIPRO COMPANY

## Makoto™ Intravascular Imaging System

- The **only** intravascular imaging device cleared by FDA for the identification of patients and plaques at increased risk of MACE
- The **only** dual modality intravascular imaging device on the market capable of detecting both plaque structure and composition using IVUS+NIRS
- 35-65 MHz Extended Bandwidth image gives a crisp HD-IVUS image quality that brings HD resolution and depth of penetration



Dualpro™ IVUS+NIRS Imaging Catheter works exclusively with the Makoto™ system



Unique chemogram display shows locations of lipid core plaque in the vessel, and quantifies lipid core with Lipid Core Burden Index (LCBI)

**Achieve unparalleled insights into the risk of MACE**



## The many benefits of imaging first

Coronary intravascular imaging can be performed **before**, **during**, and **after** percutaneous coronary intervention (PCI) to help optimize treatment.

### Before:

- ✓ Determine the culprit and significance of a lesion
- ✓ Obtain valuable information about lesion length, vessel size, and plaque characteristics
- ✓ Plan and optimize stent deployment, lesion coverage, and stent expansion
- ✓ Evaluate angiographically-ambiguous lesions
- ✓ Assess the risk of distal embolization (lesions with large lipid core plaque that are at increased risk)
- ✓ Assess the risk of MACE from non-flow limiting lesions

### During:

- ✓ View live IVUS imaging for more complete guidance and real-time confirmation

### After:

- ✓ Confirm proper lesion coverage
- ✓ Confirm stent placement and expansion

The goal is to better predict and prevent future coronary events with the aid of intravascular imaging.

Nipro presents options so you can choose the imaging system that BEST SUITS your treatment and cath lab needs.

We are proud to be a comprehensive provider of full-service imaging.